Effects of Intranasal Oxytocin on Functional Brain Network in Resting-state and Tasks

Beijing Normal University

Status: Completed

Conditions: Healthy

Treatments: Drug: Oxytocin; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03428906

IN-OT functional network

Details and patient eligibility

About

To investigate whether and how intranasal oxytocin of 8IU treatment will alter the topology of functional brain network in resting-state and multiple tasks in healthy males.

Full description

In a randomized, double-blind, cross-over, placebo controlled design, healthy male volunteers receive intranasal oxytocin or placebo prior to functional magnetic resonance imaging.Subjects will then go through a decision making task, a emotion judgement task and an eight-minute resting-state scan in MRI scanner to investigate whether and how intranasal oxytocin alter the topology of functional brain network in resting-state and multiple tasks in healthy males. State anxiety and mood are measured before and after experiment as covariates to be controlled.

Enrollment: 34 patients

Sex: Male

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy subjects without past or current psychiatric or neurological disorders

Exclusion criteria

• with MRI Contraindications

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

34 participants in 2 patient groups, including a placebo group

Oxytocin

Experimental group

Description:

Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .

Treatment:

Drug: Oxytocin

Placebo

Placebo Comparator group

Description:

Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.

Treatment:

Drug: Placebo